Murphy Robin J, Godfrey Kate, Shaw Alexander D, Muthukumaraswamy Suresh, Sumner Rachael L
School of Pharmacy, University of Auckland, Auckland, New Zealand.
Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London, UK.
BMC Neurosci. 2024 Feb 5;25(1):7. doi: 10.1186/s12868-024-00844-5.
Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have demonstrated enhancing effects on neuroplasticity, which cannot be measured directly in humans, but may be indexed by non-invasive electroencephalography (EEG) paradigms. This study used a visual long-term potentiation (LTP) EEG paradigm to test the effects of microdosed lysergic acid diethylamide (LSD) on neural plasticity, both acutely while on the drug and cumulatively after microdosing every third day for six weeks. Healthy adult males (n = 80) completed the visual LTP paradigm at baseline, 2.5 h following a dose of 10 µg of LSD or inactive placebo, and 6 weeks later after taking 14 repeated microdoses. Visually induced LTP was used as indirect index of neural plasticity. Surface level event-related potential (ERPs) based analyses are presented alongside dynamic causal modelling of the source localised data using a generative thalamocortical model (TCM) of visual cortex to elucidate underlying synaptic circuitry.
Event-related potential (ERP) analyses of N1b and P2 components did not show evidence of changes in visually induced LTP by LSD either acutely or after 6 weeks of regular dosing. However modelling the complete timecourse of the ERP with the TCM demonstrated changes in laminar connectivity in primary visual cortex. This primarily included changes to self-gain and inhibitory input parameters acutely. Layer 2/3 to layer 5 excitatory connectivity was also different between LSD and placebo groups. After regular dosing only excitatory input from layer 2/3 into layer 5 and inhibitory input into layer 4 were different between groups.
Without modulation of the ERPs it is difficult to relate the findings to other studies visually inducing LTP. It also indicates the classic peak analysis may not be sensitive enough to demonstrate evidence for changes in LTP plasticity in humans at such low doses. The TCM provides a more sensitive approach to assessing changes to plasticity as differences in plasticity mediated laminar connectivity were found between the LSD and placebo groups.
ANZCTR registration number ACTRN12621000436875; Registered 16/04/2021 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476 .
微剂量使用迷幻药是一种声称具有认知益处的现象,但在临床上相对未经测试。在临床前研究中,迷幻药已显示出对神经可塑性的增强作用,这种作用无法在人体中直接测量,但可以通过非侵入性脑电图(EEG)范式进行索引。本研究使用视觉长期增强(LTP)EEG范式来测试微剂量麦角酸二乙酰胺(LSD)对神经可塑性的影响,包括在服药期间的急性影响以及每隔三天微剂量给药六周后的累积影响。80名健康成年男性在基线、服用10μg LSD或无活性安慰剂2.5小时后以及服用14次重复微剂量6周后完成了视觉LTP范式。视觉诱发的LTP被用作神经可塑性的间接指标。基于表面水平事件相关电位(ERP)的分析与使用视觉皮层的生成性丘脑皮质模型(TCM)对源定位数据进行动态因果建模一起呈现,以阐明潜在的突触回路。
对N1b和P2成分的事件相关电位(ERP)分析未显示LSD在急性给药或常规给药6周后对视觉诱发的LTP有变化的证据。然而,用TCM对ERP的完整时间过程进行建模表明初级视觉皮层的层状连接性发生了变化。这主要包括急性时自我增益和抑制性输入参数的变化。LSD组和安慰剂组之间第2/3层到第5层的兴奋性连接也有所不同。在常规给药后,仅第2/3层到第5层的兴奋性输入以及第4层的抑制性输入在组间存在差异。
如果没有ERP的调节,很难将这些发现与其他视觉诱发LTP的研究联系起来。这也表明经典的峰值分析可能不够敏感,无法证明在如此低剂量下人体LTP可塑性变化的证据。TCM提供了一种更敏感的方法来评估可塑性的变化,因为在LSD组和安慰剂组之间发现了可塑性介导的层状连接性差异。
澳大利亚和新西兰临床试验注册中心注册号ACTRN12621000436875;2021年4月16日注册https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476 。